Mink Therapeutics Inc expected to post a loss of 23 cents a share - Earnings Preview

Mink Therapeutics

01/11/2022 17:48

* Mink Therapeutics Inc  INKT.OQ   INKT.O  is expected
to show no
change in quarterly revenue when it reports  results on November
3. 
    * 
    * ​Refinitiv's mean analyst estimate for Mink Therapeutics
Inc is
for a loss of 23 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Mink
Therapeutics
Inc is $7​, above​ its last closing price of $2.18. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Jun. 30 2022  -0.24       -0.24      -0.18     Beat    25
 Mar. 31 2022  -0.21       -0.21      -0.23     Missed  -11.3
 Dec. 31 2021  -0.41       -0.41      -0.18     Beat    56.1​
 Sep. 30 2021  -0.20       -0.20      -0.59     Missed  -187.8
 ​​                                                     
                                                        ​
 This summary was machine generated November 1 at 17:48 GMT.  All
figures in US dollars  unless otherwise stated